EXUMA Biotech Corp. is a clinical-stage biotechnology company headquartered in West Palm Beach, Florida, focused on discovering and developing innovative cell therapies and oncology treatments.
Subscribe to see EXUMA Biotech Corp.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
EXUMA Biotech Corp. is a company headquartered in United States. Its most recent funding round raised $70M in May 2026. Xcout tracks 6 named people at EXUMA Biotech Corp., including Gregory Frost (Executive Officer).
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $70M | — | |
| Series B | $19M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of EXUMA Biotech Corp.'s closest competitors — see the full list of competitors and alternatives →
Eureka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative technology platforms and first-in-class T-cell therapies to access cancer-specific targets.
Kaida BioPharma Inc. is a biotechnology company operating in the deep-tech therapeutic R&D sector with a corporate office located in Fort Lauderdale, Florida.
Bellicum Pharmaceuticals, Inc. is a company focused on engineering high-performance cellular immunotherapies. These therapies are developed to combat diseases.
ImmPACT Bio USA, Inc. is a clinical-stage biotechnology company headquartered in West Hills, California. The company focuses on developing advanced cell therapies and immunotherapies to treat cancer and other serious diseases.
Arcellx, Inc. is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, dedicated to developing innovative immunotherapies and cell therapies for cancer patients.
Aegle Therapeutics Corp. is a clinical-stage biotechnology company headquartered in Miami, Florida, with additional operations in Woburn, Massachusetts. The company is a leader in developing novel extracellular vesicle therapies to treat various diseases and disorders.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.